Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sensory boost helps cancer patients stay steady

NCT ID NCT07027215

Symptom relief Sponsor: Isra University, Jordan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether adding extra sensory feedback to physical therapy could improve balance and reduce fall risk in women with nerve damage from cancer treatment. Forty women who had recovered from breast cancer took part. The group that received the extra sensory feedback showed better balance and foot sensitivity compared to those who only did standard exercises.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
physical therapy with augmented sensory feedback (intermittent pneumatic compression, balance exercises, PNF technique)
What this could lead to
If it works, this could point toward a better way to help cancer survivors with nerve damage improve their balance and reduce falls.
What could go wrong
This was a small, completed study with only 40 women, so results may not apply to everyone. The improvements seen may not hold up in larger, more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Jan 2024

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 60 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Forty female with age from 35-60 years * clinically diagnosed with CIPN after recovery from stage I or II breast cancer * The strength at the toes, ankles, knees, and hips, as determined by manual muscle tests, of at least 3/5. * The patients can walk independently with or without any assistive devices. Exclusion Criteria: * Patients with a history of hereditary peripheral neuropathy * Diseases that may contribute to peripheral nerve damage, such as diabetes or renal insufficiency, alcohol abuse, HIV, and vasculitis. * Patient who had central or peripheral neurologic disease, brain or spinal cord metastases * Orthopedic problems influencing gait, or foot ulcer at the moment of intake. * Patients with vestibular or neurological problems influencing gait parameters * Subjects who had participated in regular exercise, as defined as 150 min of light-to-moderate intensity exercise per week over the past year, were excluded from this trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy-induced peripheral neuropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chemotherapy-induced neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Physical therapy

Contacts and locations

Locations

  • Faculty of Physical Therapy South Valley University

    Luxor, Qena Governorate, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.